119 related articles for article (PubMed ID: 11412986)
1. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
Weiss KL; Alshafie G; Chapman JS; Mershon SM; Abou-Issa H; Clagett-Dame M; Curley RW
Bioorg Med Chem Lett; 2001 Jun; 11(12):1583-6. PubMed ID: 11412986
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
3. An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
Walker JR; Alshafie G; Abou-Issa H; Curley RW
Bioorg Med Chem Lett; 2002 Sep; 12(17):2447-50. PubMed ID: 12161154
[TBL] [Abstract][Full Text] [Related]
4. Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.
Mershon SM; Anding AL; Chapman JS; Clagett-Dame M; Stonerock LA; Curley RW
Bioorg Med Chem Lett; 2007 Feb; 17(3):836-40. PubMed ID: 17112722
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
Walker JR; Alshafie G; Nieves N; Ahrens J; Clagett-Dame M; Abou-Issa H; Curley RW
Bioorg Med Chem; 2006 May; 14(9):3038-48. PubMed ID: 16412653
[TBL] [Abstract][Full Text] [Related]
6. The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor.
Anding AL; Chapman JS; Barnett DW; Curley RW; Clagett-Dame M
Cancer Res; 2007 Jul; 67(13):6270-7. PubMed ID: 17616685
[TBL] [Abstract][Full Text] [Related]
7. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
[TBL] [Abstract][Full Text] [Related]
9. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M
Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
12. Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye.
Lewis KC; Zech LA; Phang JM
Eur J Cancer; 1996 Sep; 32A(10):1803-8. PubMed ID: 8983293
[TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver.
Matsuura T; Zhao Z; Ross AC
J Nutr; 1996 Oct; 126(10):2474-80. PubMed ID: 8857507
[TBL] [Abstract][Full Text] [Related]
14. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells.
Bunk MJ; Kinahan JJ; Sarkar NH
Cancer Lett; 1985 Apr; 26(3):319-26. PubMed ID: 2986832
[TBL] [Abstract][Full Text] [Related]
16. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
17. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
18. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
19. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
20. The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: structure-activity relationships and retinoid receptor-independent anticancer activities.
Dawson MI; Fontana JA
Mini Rev Med Chem; 2010 Jun; 10(6):455-91. PubMed ID: 20370709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]